Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression
- 577 Downloads
Surrogate measures of fracture risk, such as effects on bone mineral density, may be of great interest to assess the efficacy of available osteoporosis treatments. Our results suggest that bone mineral density (BMD) changes cannot be used as a surrogate of anti-fracture efficacy, among patients receiving calcium, with or without vitamin D.
The purpose of this study is to examine the association between changes in bone mineral density with reduction in the risk of fractures in patients receiving calcium with or without vitamin D.
We selected all randomized placebo-controlled clinical trials of calcium with or without vitamin D supplementation. To be included in this analysis, the studies were required to report both BMD (hip/proximal femur and/or lumbar spine) and the incidence of fractures. Meta-regression analyses were used to examine the associations of changes in BMD with reduction in risk of fracture over the duration of each study. The change in BMD was the difference between changes (from baseline) observed in the active treatment group and placebo group.
A total of 15 randomized trials (n = 47,365) were identified, most of whom (77%) came from the Women’s Health Initiative trial. Results show that larger increases in BMD at the lumbar spine were not associated with greater reduction in fracture risk. Concerning hip BMD changes, we found a statistically significant relationship between hip BMD changes and reduction in risk. However, results were not quite significant after excluding the both largest studies, in which BMD changes were measured in very small subset of patients. These points may have largely biased our results.
In conclusion, there was no evidence of a relationship between BMD changes and reduction in risk of fractures among patients receiving calcium with or without vitamin D supplementation. Calcium and/or Vitamin D may reduce fracture rates through a mechanism independent of bone density.
KeywordsBone mineral density Calcium Fracture Meta-regression Vitamin D
This study has been supported by a research grant from Nycomed. However, Nycomed had no control in study design, data collection and analysis, interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.
Conflicts of interest
No particular conflict of interest for this particular study. However, Véronique Rabenda, Olivier Bruyère, and Jean-Yves Reginster have received research grants and/or consulting fees from pharmaceutical companies.
- 2.Temple RJ (1995) A regulatory authority’s opinion about surrogate endpoints. In: Nimmo WS, Tucker GT (eds) Clinical measurement in drug evaluation. Wiley, New YorkGoogle Scholar
- 3.Li Z, Chines AA, Meredith MP (2004) Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? J Musculoskelet Neuron Interact 4:6474Google Scholar
- 11.Hatal R, Keitz S, Wyer P, Guyatt G, on behalf of the Evidence-Based Medicine Teaching Tips Working Group (2005) Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ 172:661–665Google Scholar
- 16.Fujita T, Ohue M, Fujii Y, Miyauchi A, Takagi Y (2004) Reappraisal of Katsuragi calcium study, a prospective, double-blind, placebo-controlled study of the effect of active absorbable algal calcium (AAACa) on vertebral deformity and fracture. J Bone Miner Metab 22(1):32–38CrossRefPubMedGoogle Scholar
- 22.Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Meunier PJ (2002) Combined calcium and vitamin D3 supplementation in elderly women:confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 13:257–264CrossRefPubMedGoogle Scholar
- 25.Bolton-Smith C, McMurdo ME, Paterson CR, Mole PA, Harvey JM, Fenton ST, Prynne CJ, Mishra GD, Shearer MJ (2007) Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women. J Bone Miner Res 22(4):509–519CrossRefPubMedGoogle Scholar
- 26.Salovaara K, Tuppurainen M, Kärkkäinen M, Rikkonen T, Sandini L, Sirola J, Honkanen R, Alhava E, Kröger H (2010) Effect of vitamin D3 and calcium on fracture risk in 65- to 71-year-old women: a population-based 3-year randomized, controlled trial—The OSTPRE-FPS. JBMR 25:1487–1495CrossRefGoogle Scholar
- 28.Watts NB, Cooper C, Lindsay R et al (2004) Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255–261CrossRefPubMedGoogle Scholar
- 30.Hochberg MC, Ross PD, Black D, Fracture Intervention Trial Research Group et al (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 42:1246–1254CrossRefPubMedGoogle Scholar
- 31.Bruyère O, Roux C, Badurski J et al (2007) Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 23:3076–3081Google Scholar
- 36.Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, The Fracture Intervention Trial Study Group et al (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250–1258CrossRefPubMedGoogle Scholar
- 38.International Society for Clinical Densitometry. Official positions. Available at: www.iscd.org
- 39.National Osteoporosis Foundation. New clinicians guide to prevention and treatment of osteoporosis. Available at: www.nof.org